ReviewEuropean journal of nuclear medicine and molecular imaging2023
PET molecular imaging for pathophysiological visualization in Alzheimer's disease.
Review in European journal of nuclear medicine and molecular imaging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 61 citations in OpenAlex.
- Amyloid-β PET Radioligands in Alzheimer's Disease: From Plaque Detection to Biomarker-Guided Patient Stratification and Therapeutic Monitoring.Molecular diagnosis & therapy · 2026Review
- The clinical Alzheimer's disease spectrum classified in the A/T/N framework withEuropean journal of nuclear medicine and molecular imaging · 2026Observational
- Review
- Clinical translation of fluid, imaging, and digital biomarkers for Alzheimer's disease.Alzheimer's research & therapy · 2026Review
- A causal deep learning approach to identifying metabolic signatures of cognitive and functional decline in alzheimer's disease.Scientific reports · 2026Article
- Neuronal plasticity and its role in Alzheimer's disease and Parkinson's disease.Neural regeneration research · 2026Article
- High-dimensional inference for functional regression with an application to the Alzheimer's disease magnetoencephalography study.Biostatistics (Oxford, England) · 2025Article
- Material-based neuroimaging and biomarker detection for central nervous system disorder.Materials today. Bio · 2025Review
- NADPH Oxidase Inhibition Promotes Brain Resilience by Attenuating Tauopathy and Neuroinflammation in Alzheimer's Disease.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Potential Off-Target Interaction of the Amyloid PET Imaging Tracer PiB with Acetylcholinesterase.ACS omega · 2025Article
- A novel electric field approach for improving cognitive function through ameliorating cell-specific pathology in P301S tauopathy mice.Alzheimer's research & therapy · 2025Article
- Establishing cutoff values for visual amyloid positivity in [EJNMMI research · 2025Article
- Biomarkers of cognitive and memory decline in psychotropic drug users.Journal of neural transmission (Vienna, Austria : 1996) · 2025Review
- Changes in choroidal thickness quantified by Optical Coherence Tomography across cognitive impairment: data from the NORFACE cohort.Alzheimer's research & therapy · 2024Article
- Updates in Alzheimer's disease: from basic research to diagnosis and therapies.Translational neurodegeneration · 2024Review
- [Construction and analysis of brain metabolic network in temporal lobe epilepsy patients based onSheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi · 2024Article
- Alzheimer's disease stage recognition from MRI and PET imaging data using Pareto-optimal quantum dynamic optimization.Heliyon · 2024Article
- Novel β-amyloid PET Imaging Study of [ACS omega · 2024Article
- Article
- Anti-amyloid Antibody Therapies for Alzheimer's Disease.Nuclear medicine and molecular imaging · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
Alzheimer's disease (AD) is the most common dementia worldwide. The exact etiology of AD is unclear as yet, and no effective treatments are currently available, making AD a tremendous burden posed on the whole society. As AD is a multifaceted and heterogeneous disease, and most biomarkers are dynamic in the course of AD, a range of biomarkers should be established to evaluate the severity and prognosis. Positron emission tomography (PET) offers a great opportunity to visualize AD from diverse perspectives by using radiolabeled agents involved in various pathophysiological processes; PET imaging technique helps to explore the pathomechanisms of AD comprehensively and find out the most appropriate biomarker in each AD phase, leading to a better evaluation of the disease. In this review, we discuss the application of PET in the course of AD and summarized radiolabeled compounds with favorable imaging characteristics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.